Complete financial analysis of Monte Rosa Therapeutics, Inc. (GLUE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Monte Rosa Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Ways Technical Corp., Ltd. (3508.TWO) Income Statement Analysis – Financial Results
- Foster Electric Company, Limited (6794.T) Income Statement Analysis – Financial Results
- Sigurd Microelectronics Corporation (6257.TW) Income Statement Analysis – Financial Results
- CopAur Minerals Inc. (CPAU.V) Income Statement Analysis – Financial Results
- New Focus Auto Tech Holdings Limited (0360.HK) Income Statement Analysis – Financial Results
Monte Rosa Therapeutics, Inc. (GLUE)
About Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 6.22M | 8.56M | 2.13M | 537.00K | 72.00K |
| Gross Profit | -6.22M | -8.56M | -2.13M | -537.00K | -72.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 105.05M | 85.06M | 57.16M | 24.01M | 7.35M |
| General & Administrative | 32.04M | 27.32M | 15.73M | 4.01M | 644.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 32.04M | 27.32M | 15.73M | 4.01M | 644.00K |
| Other Expenses | 0.00 | 0.00 | -960.00K | -7.68M | 276.00K |
| Operating Expenses | 143.31M | 112.38M | 72.88M | 28.01M | 7.99M |
| Cost & Expenses | 143.31M | 112.38M | 72.88M | 28.01M | 7.99M |
| Interest Income | 9.33M | 3.76M | 46.00K | 9.00K | 12.00 |
| Interest Expense | 0.00 | 3.76M | 0.00 | 0.00 | 1.00K |
| Depreciation & Amortization | 6.22M | 8.56M | 2.13M | 537.00K | 72.00K |
| EBITDA | -137.09M | -99.94M | -70.75M | -27.47M | -7.67M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -143.31M | -112.38M | -72.88M | -28.01M | -7.99M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 8.30M | 3.88M | -1.08M | -7.87M | 254.00K |
| Income Before Tax | -135.01M | -108.50M | -73.96M | -35.88M | -7.74M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 338.00K | -3.88M | -2.02M | 189.00K | 277.00K |
| Net Income | -135.35M | -104.62M | -71.94M | -36.07M | -8.02M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.63 | -2.22 | -1.55 | -0.82 | -0.18 |
| EPS Diluted | -2.63 | -2.22 | -1.55 | -0.82 | -0.18 |
| Weighted Avg Shares Out | 51.40M | 47.23M | 46.54M | 44.00M | 44.00M |
| Weighted Avg Shares Out (Dil) | 51.40M | 47.23M | 46.54M | 44.00M | 44.00M |
Monte Rosa Therapeutics to Present Late-breaking Preclinical Data on Targeting GSPT1 for Myc-driven Cancers at AACR-NCI-EORTC Virtual International Conference
Monte Rosa Therapeutics Announces Addition to Russell 2000® and Russell 3000® Indexes
Monte Rosa Therapeutics to Participate in Morgan Stanley 19th Annual Global Healthcare Conference
Monte Rosa Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Pipeline and Business Progress
6 Companies Are Making Their Trading Debuts. What Investors Need to Know.
Monte Rosa Therapeutics Announces Pricing of Initial Public Offering
Source: https://incomestatements.info
Category: Stock Reports